<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tropisetron is widely used to counteract chemotherapy-induced <z:hpo ids='HP_0002013'>emesis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Evidence obtained from human and animal studies shows that tropisetron possesses anti-inflammatory properties </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we assessed the effect of tropisetron on brain damage in a rat thromboembolic model of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001297'>Stroke</z:hpo> was rendered in rats by introduction of an autologous clot into the middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) </plain></SENT>
<SENT sid="4" pm="."><plain>Tropisetron (1 or 3mg/kg); m-chlorophenylbiguanide (mCPBG), a selective <z:chebi fb="0" ids="28790">5-HT</z:chebi>(3) receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> (15 mg/kg); tropisetron (3mg/kg) plus mCPBG (15 mg/kg); granisetron (3mg/kg); tacrolimus (1mg/kg); or tacrolimus (1mg/kg) plus tropisetron (3mg/kg) were administered intraperitoneally 1h prior to embolization </plain></SENT>
<SENT sid="5" pm="."><plain>Behavioral scores and <z:mpath ids='MPATH_124'>infarct</z:mpath> volume as well as myeloperoxidase (MPO) activity and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-α) level were determined in the ipsilateral cortex 4h and 48 h following <z:hpo ids='HP_0001297'>stroke</z:hpo> induction </plain></SENT>
<SENT sid="6" pm="."><plain>Forty-eight hours after embolization, tropisetron (1 or 3mg/kg), tropisetron (3mg/kg) plus mCPBG (15 mg/kg), tacrolimus (1mg/kg), or tacrolimus (1mg/kg) plus tropisetron (3mg/kg) significantly curtailed <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>, improved behavioral scores, diminished elevated tissue MPO activity, and reduced TNF-α levels compared to control group (n=6; P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>mCPBG or granisetron had no effect on the mentioned parameters </plain></SENT>
<SENT sid="8" pm="."><plain>Tropisetron attenuates brain damage after a thromboembolic event </plain></SENT>
<SENT sid="9" pm="."><plain>Beneficial effects of tropisetron in this setting are receptor independent </plain></SENT>
</text></document>